Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Feature|Videos|October 8, 2025
The Importance of Excipient Grade
Author(s)Nigel Langley, gChem
In this interview, Dr Nigel Langley of gChem discusses the importance of excipient grade, compliance, and supply chain transparency, and introduces PROCIPIENT®, gChem’s high-purity pharmaceutical-grade DMSO.
Sponsored by gChem
In this interview, Dr Nigel Langley of gChem explores the critical importance of excipient grade in pharmaceutical formulation for both industry and academia. He discusses how purity and functionality impact drug development, the risks of “Testing Up,” and the challenges of excipient interchangeability. Dr Langley also highlights the need for collaborative supplier relationships, transparent supply chains, and strict compliance with cGMP standards. He concludes by sharing how gChem supports the pharmaceutical industry with PROCIPIENT®, its high-purity pharmaceutical-grade dimethyl sulfoxide (DMSO), manufactured to meet pharmacopeia specifications.
Learning Objectives:
- Understand the importance of selecting the appropriate grade of excipient in drug formulation.
- Recognize the value of collaborative supplier relationships and full supply chain traceability.
- Appreciate the role of quality and compliance in ensuring materials are manufactured under cGMP and meet pharmacopeia specifications.
- Learn how gChem provides confidence with PROCIPIENT®, its high-purity pharmaceutical-grade DMSO.
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.